Kura Oncology Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Kura Oncology's estimated annual revenue is currently $5.7M per year.
- Kura Oncology received $Undisclosed in venture funding in August 2017.
- Kura Oncology's estimated revenue per employee is $119,479
- Kura Oncology's total funding is $205M.
- Kura Oncology has 48 Employees.
- Kura Oncology grew their employee count by 14% last year.
- Kura Oncology currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Kura Oncology?
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development. For additional information, please visit our website at www.kuraoncology.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Kura Oncology News
On Thursday, shares of Kura Oncology, Inc. (NASDAQ:KURA) marked $16.14 per share versus a previous $15.24 closing price. With having a ...
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused ...
03, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the ...
Kura Oncology Funding
Kura Oncology Executive Hires
|2018-06-21||John Farnam||Chief Operating Officer||Article|
|2018-08-01||Marc Grasso||CFO & Chief Business Office||Article|